Eikon Therapeutics, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
EIKN
Eikon Therapeutics, Inc. Common Stock
$10.83 -1.19%
VS HALOHalozyme Therapeutics, Inc.
$110.76 +1.00%
Eikon Therapeutics, Inc. Common Stock (EIKN) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| EIKN | HALO | |
|---|---|---|
| Market Cap | $593.65 million | $12.45 billion |
| Revenue (TTM) | — | $1.66 billion |
| Net Income (TTM) | — | $413.60 million |
HALO leads on 1 of 1 size & scale factors.
Valuation
| EIKN | HALO | |
|---|---|---|
| P/E Ratio | — | 32.29 |
| Price / Book | 1.27 | 86.71 |
| Price / Sales | — | 7.48 |
EIKN leads on 1 of 1 valuation factors.
Profitability
| EIKN | HALO | |
|---|---|---|
| Net Margin | — | 24.86% |
| Return on Equity | — | 288.13% |
EIKN and HALO split the profitability factors evenly.
Risk & Sentiment
| EIKN | HALO | |
|---|---|---|
| Short Interest | 1.60% | 9.79% |
EIKN leads on 1 of 1 risk & sentiment factors.
Dig deeper: EIKN overview, EIKN financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.